Actinogen Medical Limited

Actinogen is an ASX-listed, biotech company conducting Ph 2 trials of an oral, brain-penetrant small molecule for Alzheimer’s Disease (AD) and cognitive impairment associated with Depression. Xanamem® works by a novel, non-amyloid mechanism to reduce tissue cortisol by inhibition of the intracellular enzyme, 11β-HSD1. Cortisol is strongly associated with detrimental brain changes affecting cognition.

Xanamem safety has been demonstrated in >300 people treated to date. Improved attention & working memory were seen in 2 randomized trials & clinically significant improvements in function & cognition in mild AD patients were observed in a 3rd randomized trial.

A Ph 2b trial in 330 patients with early-stage AD will commence soon & a Ph 2a trial in 160 patients with depression & cognitive impairment initiated in Dec 2022.

Actinogen is proactively engaging with prospective global and regional biopharma partners that wish to collaborate on development and commercialization of Xanamem.